Myotubularin-related protein 7 activates peroxisome proliferator-activated receptor-gamma

Oncogenesis
Philip WeidnerElke Burgermeister

Abstract

Peroxisome proliferator-activated receptor-gamma (PPARγ) is a transcription factor drugable by agonists approved for treatment of type 2 diabetes, but also inhibits carcinogenesis and cell proliferation in vivo. Activating mutations in the Kirsten rat sarcoma viral oncogene homologue (KRAS) gene mitigate these beneficial effects by promoting a negative feedback-loop comprising extracellular signal-regulated kinase 1/2 (ERK1/2) and mitogen-activated kinase kinase 1/2 (MEK1/2)-dependent inactivation of PPARγ. To overcome this inhibitory mechanism, we searched for novel post-translational regulators of PPARγ. Phosphoinositide phosphatase Myotubularin-Related-Protein-7 (MTMR7) was identified as cytosolic interaction partner of PPARγ. Synthetic peptides were designed resembling the regulatory coiled-coil (CC) domain of MTMR7, and their activities studied in human cancer cell lines and C57BL6/J mice. MTMR7 formed a complex with PPARγ and increased its transcriptional activity by inhibiting ERK1/2-dependent phosphorylation of PPARγ. MTMR7-CC peptides mimicked PPARγ-activation in vitro and in vivo due to LXXLL motifs in the CC domain. Molecular dynamics simulations and docking predicted that peptides interact with the steroid receptor ...Continue Reading

References

Jun 8, 2000·International Journal of Cancer. Journal International Du Cancer·J ThompsonW Zimmermann
Feb 22, 2003·Journal of Molecular Biology·Alexander StarkRobert B Russell
Apr 2, 2003·Proceedings of the National Academy of Sciences of the United States of America·Soo-A KimJack E Dixon
May 3, 2003·Nature Reviews. Molecular Cell Biology·John F Hancock
Aug 2, 2003·Proceedings of the National Academy of Sciences of the United States of America·Yasuhiro Mochizuki, Philip W Majerus
Jan 7, 2004·Nature Reviews. Cancer·Liliane MichalikWalter Wahli
Mar 31, 2004·The Journal of Peptide Research : Official Journal of the American Peptide Society·R S Savkur, T P Burris
Jun 25, 2004·Nucleic Acids Research·Burkhard RostJinfeng Liu
Feb 5, 2005·Trends in Biochemical Sciences·Michael J PlevinMitsuhiko Ikura
May 19, 2007·Journal of Clinical Immunology·Julian D RamakersJogchum Plat
Jul 6, 2007·Cell Cycle·Elke Burgermeister, Rony Seger
Aug 2, 2007·Expert Opinion on Therapeutic Targets·Efstathia PapageorgiouMichael Koutsilieris
Sep 27, 2007·Bioinformatics·Sanbo Qin, Huan-Xiang Zhou
Apr 24, 2008·Traffic·Anne-Sophie Nicot, Jocelyn Laporte
Jul 4, 2008·PPAR Research·Elke Burgermeister, Rony Seger
Oct 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Geoffrey D GirnunKwok-Kin Wong
Oct 24, 2008·The New England Journal of Medicine·Christos S KarapetisJohn R Zalcberg
Dec 2, 2008·Nature·Vikas ChandraFraydoon Rastinejad
Apr 24, 2010·Nature Reviews. Immunology·Christopher K Glass, Kaoru Saijo
Sep 8, 2010·Nature Reviews. Endocrinology·Masanobu Kawai, Clifford J Rosen
Feb 10, 2012·Nature Reviews. Cancer·Jeffrey M PetersFrank J Gonzalez
Apr 20, 2012·Trends in Endocrinology and Metabolism : TEM·Bertrand CariouBart Staels
May 15, 2012·Trends in Molecular Medicine·Karim HniaJocelyn Laporte
Jun 1, 2012·Proceedings of the National Academy of Sciences of the United States of America·Jun ZouMonita P Wilson
Aug 21, 2013·Nature Reviews. Cancer·Niall TebbuttTerrance G Johns
Sep 3, 2013·The New England Journal of Medicine·William R HiattRobert J Smith
Jan 23, 2014·Toxicological Sciences : an Official Journal of the Society of Toxicology·Huamei HeJames A Balschi

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
CoIP
pulldown
proximity
transfection
nuclear translocation
FCS
myristoylation
nuclear magnetic resonance

Software Mentioned

PredictProtein
Pepwheel
EMBOSS
Agadir
DeepCoil
NCOILS
AMBER18
PPISP
PINTS
GalaxyPepDock

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Related Papers

Current Hypertension Reports
Madeliene StumpCurt D Sigmund
Journal of Immunoassay & Immunochemistry
Siu-Lung Chan, Marilyn J Cipolla
Current Cancer Drug Targets
Piotr Mrowka, Eliza Glodkowska-Mrowka
© 2022 Meta ULC. All rights reserved